Memory Center – Research Trials
Clinical trials are designed to determine if a new treatment will be both safe and effective for patients. In addition, trials will often collect data to determine whether an investigational strategy will have a broader influence on related problems such as activities of daily living, caregiver stress or general quality of life.
Clinical trials in Alzheimer’s disease will usually involve both patients and caregivers. While trial participation is completely voluntary, it is important to recognize the time and effort involved in the successful completion of a clinical trial.
The Memory Center is gratified to be able to offer our community access to potential new treatments for Alzheimer’s. New treatments can only be discovered through the partnership of patient volunteers, research sites, and scientific sponsors. Everyone plays an important role in this investigational process. Every day, we work with hopeful optimism towards more effective therapies, more accurate diagnoses, and eventually a sustainable cure for Alzheimer’s disease.
None of this happens without your help.
AWARE Study (M15-566) NCT02880956
- A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease
- The Aware Study is evaluating an investigational medication that targets a protein called tau, which builds-up in the brains of people with Early Alzheimer’s disease.
- For more information, visit www.theawarestudy.com
elevage (TTP488-305) Identifier: NCT03980730
- This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer’s disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient’s participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).
EMBARK (221AD304) NCT04241068
- Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
H8A-US-B004 (GERAS-US) Identifier: NCT02951598
- The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered
The GAIN Trial (COR388-010) Identifier: NCT03823404
- This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia.
- For more information, visit www.gaintrial.com
The Memory Center provides patients in south Mississippi with access to leading-edge clinical trials and care for those suffering with Alzheimer’s disease, dementia and other cognitive impairment disorders. By partnering with both academia and industry, the Memory Center is able to integrate research studies into the flow of clinical neurology practice.